3′-Deoxy-3′-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients

被引:34
|
作者
Idema, Albert J. S. [1 ]
Hoffmann, Aswin L. [2 ,3 ]
Boogaarts, Hieronymus D. [1 ]
Troost, Esther G. C. [2 ,3 ]
Wesseling, Pieter [4 ,5 ]
Heerschap, Arend [6 ]
van der Graaf, Winette T. A. [7 ]
Grotenhuis, J. Andre [1 ]
Oyen, Wim J. G. [8 ]
机构
[1] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[4] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[5] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands
[6] Radboud Univ Nijmegen, Dept Radiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[7] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Dept Nucl Med, Med Ctr, NL-6500 HB Nijmegen, Netherlands
关键词
PET/CT; F-18-fluorothymidine; FLT; high-grade glioma; overall survival; POSITRON-EMISSION-TOMOGRAPHY; IMAGING PROLIFERATION; MALIGNANT GLIOMA; F-18-FLT PET; BRAIN-TUMORS; NECK-CANCER; TRIAL; SEGMENTATION; GLIOBLASTOMA; BEVACIZUMAB;
D O I
10.2967/jnumed.112.105544
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a radiopharmaceutical depicting tumor cell proliferation with PET. In malignancies of the lung, breast, head and neck, digestive tract, brain, and other organs, quantitative assessment of F-18-FLT targeting has been shown to correlate with the proliferation marker Ki-67 and with clinical outcome measures such as time to progression and overall survival (OS). The aim of this study was to assess various PET segmentation methods to estimate the proliferative volume (PV) and their prognostic value for OS in patients with suspected high-grade glioma. Methods: Twenty-six consecutive patients underwent preoperative F-18-FLT PET/CT and T1-weighted MRI of the brain after contrast application. The maximum standardized uptake value (SUVmax) of all tumors was calculated, and 3 different segmentation methods for estimating the PV were used: the 50% isocontour of the SUVmax signal for the PV50%, the signal-to-background ratio (SBR) for an adaptive threshold delineation (PVSBR) method, and the iterative background-subtracted relative threshold level (RTL) method to estimate the PVRTL. The prognostic value of the SUVmax and the different PVs for OS were assessed. Results: Twenty-two patients had glioblastoma multiforme, 2 had anaplastic oligodendroglioma, 1 had anaplastic ependymoma, and 1 had anaplastic astrocytoma. The median OS was 397 d (95% confidence interval, 204-577); 19 patients died during the follow-up period. The PVSBR showed a significantly (P = 0.002) better association with OS than did SUVmax, PVRTL, and PV50%. Receiver-operating-characteristic analysis resulted in a threshold volume for the PVSBR of 11.4 cm(3), with a sensitivity and specificity of 70% and 83%, respectively, for the prediction of OS. Kaplan-Meier analyses showed a significant discrimination between short and long OS (P = 0.024, log rank) for this threshold. Conclusion: The PV as determined by F-18-FLT PET is associated with OS in high-grade malignant gliomas. The SBR method yielded the best results to predict short and long OS.
引用
收藏
页码:1904 / 1910
页数:7
相关论文
共 50 条
  • [1] 3′-Deoxy-3′-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab
    Schwarzenberg, Johannes
    Czernin, Johannes
    Cloughesy, Timothy F.
    Ellingson, Benjamin M.
    Pope, Whitney B.
    Geist, Cheri
    Dahlbom, Magnus
    Silverman, Daniel H. S.
    Satyamurthy, Nagichettiar
    Phelps, Michael E.
    Chen, Wei
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (01) : 29 - 36
  • [2] Kinetics of 3′-Deoxy-3′-18F-Fluorothymidine During Treatment Monitoring of Recurrent High-Grade Glioma
    Schiepers, Christiaan
    Dahlbom, Magnus
    Chen, Wei
    Cloughesy, Timothy
    Czernin, Johannes
    Phelps, Michael E.
    Huang, Sung-Cheng
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) : 720 - 727
  • [3] Prognostic value of 3′-Deoxy-3′-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas
    Zhao, Fen
    Cui, Yunfeng
    Li, Minghuan
    Fu, Zheng
    Chen, Zhaoqiu
    Kong, Li
    Yang, Guoren
    Yu, Jinming
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (08) : 710 - 715
  • [4] Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements
    Hatt, Mathieu
    Rest, Catherine Cheze-Le
    Aboagye, Eric O.
    Kenny, Laura M.
    Rosso, Lula
    Turkheimer, Federico E.
    Albarghach, Nidal M.
    Metges, Jean-Philippe
    Pradier, Olivier
    Visvikis, Dimitris
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1368 - 1376
  • [5] Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
    Wardak, Mirwais
    Schiepers, Christiaan
    Dahlbom, Magnus
    Cloughesy, Timothy
    Chen, Wei
    Satyamurthy, Nagichettiar
    Czernin, Johannes
    Phelps, Michael E.
    Huang, Sung-Cheng
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6553 - 6562
  • [6] Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity
    Troost, Esther G. C.
    Bussink, Johan
    Slootweg, Piet J.
    Peeters, Wenny J. M.
    Merkx, Matthias A. W.
    van der Kogel, Albert J.
    Oyen, Wim J. G.
    Kaanders, Johannes H. A. M.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) : 713 - 719
  • [7] 18F-FDG or 3′-Deoxy-3′-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma
    Wondergem, Marielle J.
    Rizvi, Saiyada N. F.
    Jauw, Yvonne
    Hoekstra, Otto S.
    Hoetjes, Nikie
    van de Ven, Peter M.
    Boellaard, Ronald
    Chamuleau, Martine E. D.
    Cillessen, Saskia A. G. M.
    Regelink, Josien C.
    Zweegman, Sonja
    Zijlstra, Josee M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 216 - 221
  • [8] Bone metastasis of a breast cancer detected by 3′-deoxy-3′-18F-fluorothymidine PET/CT
    Cochet, A.
    Berriolo-Riedinger, A.
    Girault, S.
    Rousseau, C.
    Brunotte, F.
    Couturier, O.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (05): : N45 - N46
  • [9] Dynamic small-animal PET Imaging of tumor proliferation with 3′-Deoxy-3′-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas
    Bradbury, Michelle S.
    Hambardzumyan, Dolores
    Zanzonico, Pat B.
    Schwartz, Jazmin
    Cai, Shangde
    Burnazi, Eva M.
    Longo, Valerie
    Larson, Steven M.
    Holland, Eric C.
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (03) : 422 - 429
  • [10] Early Determination of Prognosis by Interim 3′-Deoxy-3′-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma
    Lee, Hyewon
    Kim, Seok-ki
    Kim, Yong-Il
    Kim, Tae Sung
    Kang, Se Hun
    Park, Weon Seo
    Yun, Tak
    Eom, Hyeon-Seok
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 216 - 222